SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Recent Operational Highlights "The second quarter of 2025 was another record quarter for iRhythm, with growth of more than 26%, showcasing the strength of our diversified growth strateg ...

Core Viewpoint - iRhythm Technologies, Inc. reported strong financial results for Q1 2025, with revenue growth exceeding 20% year-over-year, driven by increased demand for its Zio services and expansion into new markets, including Japan [3][4]. Financial Highlights - Revenue for Q1 2025 was $158.7 million, a 20.3% increase from $131.9 million in Q1 2024 [4][8]. - Gross profit for Q1 2025 was $109.2 million, up 24.8% from $87.5 million in Q1 2024, with a gross margin of 68.8%, an increase from 66.3% in the same period last year [5][8]. - Operating expenses for Q1 2025 were $141.8 million, compared to $125.7 million in Q1 2024, primarily due to funding innovation and serving a growing patient volume [6][8]. - The net loss for Q1 2025 was $30.7 million, or a diluted loss of $0.97 per share, an improvement from a net loss of $45.7 million, or a diluted loss of $1.47 per share, in Q1 2024 [7][8]. Operational Highlights - The company achieved a milestone of 10 million patient reports since its inception, indicating strong market penetration and demand for its services [3]. - iRhythm's recent commercial launch in Japan is part of its strategy to expand its global reach, now operating in six markets outside the U.S. [3][8]. - The company presented findings at ACC.25 showing that traditional Holter monitoring often misses actionable arrhythmias, highlighting the effectiveness of its Zio long-term continuous monitor [8]. Guidance and Future Outlook - iRhythm projects full-year 2025 revenue between $690 million to $700 million, with an adjusted EBITDA margin expected to range from approximately 7.5% to 8.5% [10][8]. - The company is optimistic about future growth driven by innovative value-based care accounts and increasing demand for Zio AT services in the U.S. and the U.K. [3][8].

Core Viewpoint - iRhythm Technologies, Inc. is actively participating in the Bank of America Securities 2025 Health Care Conference, showcasing its commitment to advancing digital health solutions [1][2]. Company Overview - iRhythm Technologies, Inc. is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease through the use of wearable biosensors and cloud-based data analytics [3]. - The company utilizes proprietary algorithms to transform data from millions of heartbeats into clinically actionable information, aiming to enhance patient care and health outcomes [3]. Event Participation - iRhythm's management is scheduled to present at the conference on May 13, 2025, at 3:40 p.m. Pacific Time, with a live and archived webcast available for interested parties [2].